After finishing at $18.32 in the prior trading day, Silk Road Medical Inc (NASDAQ: SILK) closed at $17.63, down -3.77%. In other words, the price has decreased by -$0.69 from its previous closing price. On the day, 628613 shares were traded.
Ratios:
Our goal is to gain a better understanding of SILK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.97 and its Current Ratio is at 7.95. In the meantime, Its Debt-to-Equity ratio is 0.56 whereas as Long-Term Debt/Eq ratio is at 0.55.
On January 19, 2024, Stifel Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $9 to $20.
On January 03, 2024, Lake Street started tracking the stock assigning a Buy rating and target price of $20.Lake Street initiated its Buy rating on January 03, 2024, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 05 ’24 when Ballinger Kevin J. bought 11,700 shares for $16.99 per share. The transaction valued at 198,783 led to the insider holds 17,807 shares of the business.
Buchanan Lucas W. sold 9,877 shares of SILK for $169,578 on Mar 05 ’24. The COO/CFO now owns 500,925 shares after completing the transaction at $17.17 per share. On Mar 05 ’24, another insider, Davis Andrew S., who serves as the Chief Commercial Officer of the company, sold 5,481 shares for $17.17 each. As a result, the insider received 94,103 and left with 287,773 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SILK now has a Market Capitalization of 690.65M and an Enterprise Value of 586.50M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.90 while its Price-to-Book (P/B) ratio in mrq is 4.57. Its current Enterprise Value per Revenue stands at 3.31 whereas that against EBITDA is -13.01.
Stock Price History:
Over the past 52 weeks, SILK has reached a high of $46.57, while it has fallen to a 52-week low of $6.08. The 50-Day Moving Average of the stock is 16.82, while the 200-Day Moving Average is calculated to be 15.76.
Shares Statistics:
The stock has traded on average 887.72K shares per day over the past 3-months and 646.21k shares per day over the last 10 days, according to various share statistics. A total of 39.17M shares are outstanding, with a floating share count of 36.56M. Insiders hold about 6.67% of the company’s shares, while institutions hold 104.57% stake in the company. Shares short for SILK as of Mar 15, 2024 were 3.72M with a Short Ratio of 4.19, compared to 3.6M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.50% and a Short% of Float of 9.68%.
Earnings Estimates
Its stock is currently analyzed by 8 different market analysts. On average, analysts expect EPS of -$0.4 for the current quarter, with a high estimate of -$0.36 and a low estimate of -$0.42, while EPS last year was -$0.43. The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.32 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.32 and -$1.5 for the fiscal current year, implying an average EPS of -$1.39. EPS for the following year is -$1.3, with 10 analysts recommending between -$1.17 and -$1.57.
Revenue Estimates
9 analysts predict $44.68M in revenue for the current quarter. It ranges from a high estimate of $45M to a low estimate of $43.8M. As of the current estimate, Silk Road Medical Inc’s year-ago sales were $40.69M, an estimated increase of 9.80% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $49.07M, an increase of 8.30% less than the figure of $9.80% in the same quarter last year. There is a high estimate of $50.1M for the next quarter, whereas the lowest estimate is $47.6M.
A total of 9 analysts have provided revenue estimates for SILK’s current fiscal year. The highest revenue estimate was $196.7M, while the lowest revenue estimate was $194M, resulting in an average revenue estimate of $195.92M. In the same quarter a year ago, actual revenue was $177.13M, up 10.60% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $217.79M in the next fiscal year. The high estimate is $225.41M and the low estimate is $213M. The average revenue growth estimate for next year is up 11.20% from the average revenue estimate for this year.
